Desmopressin, as a "designer-drug," in the treatment of overactive bladder syndrome

Neurourology and Urodynamics
Hashim HashimP Abrams

Abstract

This study looked at whether oral desmopressin, by decreasing kidney urine production, would prolong bladder filling-time thereby increasing the time to reach maximum capacity, thus reducing overactive bladder (OAB) symptoms, and providing an alternative method of treatment to OAB sufferers. An investigator-initiated, 2-week, multi-national, multi-centre, "proof-of-concept," phase IIb, double-blind, placebo-controlled, prospective, randomized, cross-over study was conducted using 0.2 mg of oral desmopressin in adults suffering with OAB. Patients were included in the trial period if they had >or=4 voids in the first 8-hr of the day after rising, excluding the first morning void. The primary endpoint was evaluation of effectiveness of desmopressin in increasing the time to the first OAB symptom episodes during the first 8-hr following treatment. Time to first void was 8-min later on the drug than on placebo (P = 0.27). However, the drug led to one less void (3.2 vs. 4.2) in the same period (P < 0.001). There was an increase in the time to first urgency episode with a decrease in the number of urgency episodes in the drug days compared to placebo (P < 0.003). There was a subjective improvement in frequency and urgency and overall ...Continue Reading

References

May 1, 1992·Annals of Neurology·G ValiquetteJ Herbert
Jan 1, 1990·Scandinavian Journal of Urology and Nephrology·A C Kinn, P O Larsson
Sep 1, 1983·Journal of Neurology, Neurosurgery, and Psychiatry·P HiltonS L Stanton
Jun 1, 1982·British Journal of Urology·P Hilton, S L Stanton
May 1, 1995·Movement Disorders : Official Journal of the Movement Disorder Society·O SuchowerskyG Rohs
Feb 22, 2002·Neurourology and Urodynamics·Paul AbramsUNKNOWN Standardisation Sub-committee of the International Continence Society
Oct 2, 2002·Current Urology Reports·Michael GrossRodney A Appell
Oct 31, 2003·American Journal of Obstetrics and Gynecology·Gunnar LoseUNKNOWN Nocturia Study Group
May 15, 2004·BJU International·D RobinsonJ P Norgaard
Feb 14, 2006·The Journal of Urology·Paul AbramsUNKNOWN ICIQ Advisory Board
Feb 7, 2007·European Urology·Philip van KerrebroeckJens Peter Nørgaard

❮ Previous
Next ❯

Citations

Mar 2, 2010·Women's Health·Monika VijLinda Cardozo
Jun 3, 2015·BJU International·Raveen Syan, Benjamin M Brucker
Apr 14, 2010·Expert Opinion on Emerging Drugs·Monika VijLinda Cardozo
Nov 16, 2010·The Journal of Urology·Jeffrey P Weiss
Feb 20, 2009·International Journal of Urology : Official Journal of the Japanese Urological Association·Tim SchneiderMartin C Michel
Jul 14, 2011·Korean journal of urology·Young Kook HanHayoung Kim
Nov 1, 2010·Female Pelvic Medicine & Reconstructive Surgery·Hashim Hashim, Paul Abrams
Oct 19, 2019·BJU International·Rachael D SussmanBenjamin M Brucker
Jun 7, 2011·Annals of Medicine·Ariana L Smith, Alan J Wein
Mar 30, 2019·European Urology·Benoit PeyronnetJean-Nicolas Cornu
May 18, 2021·Expert Review of Clinical Pharmacology·Natasha Alford, Hashim Hashim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.